28,471 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Purchased by Wingate Wealth Advisors Inc.

Wingate Wealth Advisors Inc. bought a new position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 28,471 shares of the company’s stock, valued at approximately $134,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Renaissance Technologies LLC purchased a new position in shares of Foghorn Therapeutics during the second quarter worth about $62,000. The Manufacturers Life Insurance Company purchased a new position in Foghorn Therapeutics in the 2nd quarter worth approximately $64,000. SG Americas Securities LLC bought a new position in shares of Foghorn Therapeutics in the 3rd quarter worth $99,000. Charles Schwab Investment Management Inc. raised its position in shares of Foghorn Therapeutics by 10.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 75,495 shares of the company’s stock valued at $703,000 after buying an additional 7,000 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of Foghorn Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,898 shares of the company’s stock worth $148,000 after acquiring an additional 8,958 shares during the last quarter. Hedge funds and other institutional investors own 61.55% of the company’s stock.

Foghorn Therapeutics Trading Up 15.3 %

Shares of NASDAQ:FHTX opened at $4.75 on Monday. The stock has a market capitalization of $264.15 million, a P/E ratio of -2.47 and a beta of 3.18. The stock’s 50-day moving average price is $4.97 and its 200-day moving average price is $6.86. Foghorn Therapeutics Inc. has a 12-month low of $3.50 and a 12-month high of $10.25.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Jefferies Financial Group reduced their target price on Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $13.00 price objective (down from $20.00) on shares of Foghorn Therapeutics in a report on Tuesday, December 17th. Finally, B. Riley assumed coverage on Foghorn Therapeutics in a report on Thursday, January 30th. They set a “buy” rating and a $10.00 price objective on the stock. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $13.17.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.